Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196311 | 0.89 | MAPT (0.41) | MAPTLMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL197113 | 0.85 | MAPT (0.57) | MAPTLMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL196682 | 0.82 | IGF1R (0.49) | MAPTSMN1; SMN2TP53IGF1RACP1 | |
| SCHEMBL937298 | 0.77 | MAPT (0.64) | MAPTLMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL959150 | 0.76 | MEN1 (0.48) | MAPTLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL196377 | 0.75 | GRM4 (0.49) | MAPTRAB9ATP53 | |
| SCHEMBL196452 | 0.75 | GRM4 (0.47) | MAPTRAB9ATP53ALDH1A1 | |
| SCHEMBL196327 | 0.75 | MAPT (0.55) | MAPTLMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL936460 | 0.75 | NPC1 (0.58) | MAPTLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29501836 | 0.75 | GRM4 (0.51) | MAPTRAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500255-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | claimed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | claimed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | MAPT 4299/4885LMNA 3678/4885SMN1; SMN2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.